Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FREESIA-1: Nipocalimab in Reducing the Risk of FNAIT in At-risk Pregnancies
NCT06449651Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2024
- Primary completion
- Dec 2029
- Modality
- Monoclonal Antibodies
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial in fetal and neonatal alloimmune thrombocytopenia (FNAIT) comparing Nipocalimab with Placebo (2 arms). Primary endpoint: Fetus/Neonate with Outcome of Death or Adjudicated Severe Bleeding or Platelet Count Less Than (<) 30*10^9/L. Started Nov 2024; status: recruiting.
02
Drugs
nipocalimab
03
Conditions
fetal and neonatal alloimmune thrombocytopenia (FNAIT)
Beyond the preview
Go deeper on NCT06449651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06449651.